designer491 CG Oncology ( NASDAQ: CGON ) shares rose 10% in midday trading Friday after the drug developer reported positive final results from a Phase 2 study of its immunotherapy candidate cretostimogene in combination with Merck’s ( MRK ) Keytruda in the treatment of high risk non-muscle invasive bladder cancer, or HR-NMIBC. The study showed a complete response rate of 54% at 24 months in the intention-to-treat population. The median duration of response has not been reached in the study but exceeds 21 months, the company said .
CG Oncology added that the study also showed progression-free survival of 100% at 24 months, with no patients progressing to muscle invasive cancer or metastatic disease. The company plans to present the data on June 2 at the annual meeting of the American Society for Clinical Oncology in Chicago. CG Oncology held its initial public offering in January .
More on CG Oncology, Inc. CG Oncology: ASCO Play And Top-Line Data End Of 2024 Could Drive Further Value CG Oncology's Promising Bladder Cancer Treatment: Balancing Hope And Risk In Late-Stage Trials CG Oncology upgraded by Goldman Sachs on recent clinical data CG Oncology reports data from Phase 3 bladder cancer study Historical earnings data for CG Oncology, Inc..
